A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC

Prior treatment

• Received any traditional Chinese herbal medicine for cancer control within 14 days before the first dose;
• Required systemic corticosteroids equivalent to more than 10 mg per day of prednisone or other immunosuppressive treatment within 14 days before the first dose;
• Received a live vaccine within 4 weeks before the first dose; inactivated seasonal influenza vaccines are permitted, but live intranasal influenza vaccines are not;
• Underwent major surgery requiring general anaesthesia within 28 days before the first dose;
• Had previous allogeneic stem-cell or organ transplantation;
• Have uncontrolled pleural effusion or ascites requiring drainage within 2 weeks before enrolment;
• Have a severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment within 2 weeks before the first dose, including tuberculosis;

Other illness

• Received systemic immunostimulatory agents, including interferons, interleukin 2, or tumour necrosis factor, within 4 weeks or five half-lives before the first dose of study treatment, whichever is longer; previous cancer vaccines are permitted;
• Have active autoimmune disease or a history of autoimmune disease with a risk of recurrence;
• Have a history of interstitial lung disease or non-infectious pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, or acute lung disease;
• Have had another active malignancy within 2 years before the first dose, except the cancer under investigation or definitively treated localised cancers, including resected basal-cell or squamous-cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast;
• Have untreated chronic hepatitis B, chronic HBV infection with an HBV DNA concentration of at least 500 IU/mL (2500 copies/mL), or active hepatitis C;
• Have a known history of HIV infection;
• Have a history of severe hypersensitivity to monoclonal antibodies.

Lab values

• Have unresolved toxicities from previous anticancer treatment that have not returned to baseline or stabilised, except adverse events unlikely to pose a safety risk, such as alopecia, neuropathy, or specified laboratory abnormalities;

Other

• Have clinically significant pericardial effusion;
• Have clinically significant cardiovascular risk factors;

• Provide written informed consent and be willing and able to comply with study requirements and scheduled assessments;
• Be aged 18-75 years at the time of consent;
• Have an ECOG performance status of 0 or 1;
• Have histologically or cytologically confirmed small-cell lung cancer;
• Have radiologically confirmed limited-stage disease;
• Have achieved a complete response, partial response, or stable disease after concurrent or sequential chemoradiotherapy, according to RECIST version 1.1;
• Have a life expectancy of at least 3 months;
• Have adequate organ function.